ইস্রায়েল - হিব্রু - Ministry of Health

novartis israel ltd - etanercept - תמיסה להזרקה - etanercept 50 mg / 1 ml - etanercept

ইস্রায়েল - হিব্রু - Ministry of Health

pfizer pharmaceuticals israel ltd - adalimumab - תמיסה להזרקה - adalimumab 50 mg / 1 ml - adalimumab

ইস্রায়েল - হিব্রু - Ministry of Health

samsung bioepis il ltd, israel - adalimumab - תמיסה להזרקה - adalimumab 50 mg/ml - adalimumab

ইস্রায়েল - হিব্রু - Ministry of Health

dexcel ltd, israel - adalimumab - תמיסה להזרקה - adalimumab 50 mg/ml - adalimumab

ইস্রায়েল - হিব্রু - Ministry of Health

j-c health care ltd - golimumab - תמיסה להזרקה - golimumab 50 mg / 0.5 ml - golimumab - golimumab - rheumatoid arthritis :simponi, in combination with methotrexate, is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis when the response to disease-modifying anti-rheumatic drug (dmard) therapy including mtx has been inadequate.psoriatic arthritis :simponi, alone or in combination with methotrexate, is indicated for the treatment of adult patients with active and progressive psoriatic arthritis when the response to previous disease-modifying anti-rheumatic drug (dmard) therapy has been inadequate.ankylosing spondylitis :simponi is indicated for the treatment of adult patients with severe active ankylosing spondylitis who have responded inadequately to conventional therapy.

ইস্রায়েল - হিব্রু - Ministry of Health

eli lilly israel ltd, israel - baricitinib - טבליות מצופות פילם - baricitinib 2 mg - baricitinib

ইস্রায়েল - হিব্রু - Ministry of Health

eli lilly israel ltd, israel - baricitinib - טבליות מצופות פילם - baricitinib 4 mg - baricitinib

ইস্রায়েল - হিব্রু - Ministry of Health

eli lilly israel ltd, israel - ixekizumab - תמיסה להזרקה - ixekizumab 80 mg / 1 ml - ixekizumab

ইস্রায়েল - হিব্রু - Ministry of Health

novartis israel ltd - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 80 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension for patients in whom combination therapy is appropriate.

ইস্রায়েল - হিব্রু - Ministry of Health

novartis israel ltd - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 160 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.